IQVIA Holdings - Analyst consensus and long-term drivers

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 09:35 UTC. Details in the imprint.

IQVIA Holdings (US46266C1053) remains a core name in health care data and contract research as analysts keep a broadly positive stance on the stock. With no fresh company-specific headlines, investors on Saturday focus on the long-term business model and consensus expectations.

Analyst view on IQVIA stock

According to data from TradingKey, IQVIA shares most recently closed at about $167.77 on 06/18/2026, implying a market capitalization around $28.0 billion and a trailing price-earnings ratio near 20.7 based on reported earnings. TradingKey quote and metrics for IQV

The same overview aggregates analyst opinions as an overall "Buy" rating on the stock, with an average price target cited at approximately $228.36 per share, suggesting upside versus the recent trading level if estimates hold. TradingKey analyst consensus snapshot

Long-term earnings and growth drivers

IQVIA reports across three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, combining data, software and services for pharmaceutical and biotech customers. IQVIA corporate overview

In recent years, management has highlighted demand for real-world evidence, decentralized clinical trials and data-driven commercial execution as structural growth drivers, as life sciences companies seek to cut development timelines and improve launch productivity globally.

How the business makes money

IQVIA generates revenue mainly by selling access to curated health care data sets and analytics platforms, running clinical trials for biopharma clients and providing contract sales teams and medical affairs services, often under multi-year agreements that support recurring revenue.

Where the stock trades today

The shares of IQVIA Holdings (US46266C1053) last closed on the New York Stock Exchange at $167.77 as of 06/18/2026, 04:00 PM ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.